Details of the Drug Combination

General Information of Drug Combination (ID: DCUVUW9)

Drug Combination Name

Camptothecin Ruxolitinib

Indication

Disease Entry	Status	REF
Hodgkin lymphoma	Investigative	[1]

Component Drugs

Camptothecin DM6CHNJ

Ruxolitinib DM7Q98D

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: L-1236

Zero Interaction Potency (ZIP) Score: 0.55

Bliss Independence Score: 0.05

Loewe Additivity Score: 1.58

LHighest Single Agent (HSA) Score: 3.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Camptothecin

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]

Camptothecin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Camptothecin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[17]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[18]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[19]
------------------------------------------------------------------------------------

Camptothecin Interacts with 121 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Increases Expression	[20]
Serine/threonine-protein kinase Chk2 (CHEK2)	OT8ZPCNS	CHK2_HUMAN	Increases Expression	[14]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[21]
Transcription factor SOX-12 (SOX12)	OT93P8C9	SOX12_HUMAN	Increases Methylation	[10]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[10]
Adenomatous polyposis coli protein (APC)	OTKV0TIK	APC_HUMAN	Increases Methylation	[10]
Transcription factor SOX-11 (SOX11)	OT4LG7LA	SOX11_HUMAN	Increases Methylation	[10]
Transcription factor SOX-3 (SOX3)	OT1CRCOB	SOX3_HUMAN	Increases Methylation	[10]
Transcription factor SOX-8 (SOX8)	OTEJXYZM	SOX8_HUMAN	Increases Methylation	[10]
Transcription factor SOX-4 (SOX4)	OTSS40SS	SOX4_HUMAN	Increases Methylation	[10]
Centrosomal protein of 85 kDa-like (CEP85L)	OTSHJFOT	CE85L_HUMAN	Increases Methylation	[10]
Centrosome-associated protein ALMS1 (ALMS1)	OTW66JKS	ALMS1_HUMAN	Decreases Methylation	[10]
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12)	OT0EDNV9	GTR12_HUMAN	Increases Methylation	[10]
AMSH-like protease (STAMBPL1)	OTI4CYTF	STALP_HUMAN	Increases Methylation	[10]
Frizzled-8 (FZD8)	OTZ9IRFL	FZD8_HUMAN	Decreases Methylation	[10]
Transcription factor SOX-17 (SOX17)	OT9H4WWE	SOX17_HUMAN	Increases Methylation	[10]
Frizzled-1 (FZD1)	OTZATHVS	FZD1_HUMAN	Decreases Methylation	[10]
Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 (AGAP1)	OTVX8835	AGAP1_HUMAN	Increases Methylation	[10]
Transcription factor E2F8 (E2F8)	OTQKZGFP	E2F8_HUMAN	Increases Expression	[13]
Transmembrane protein 250 (TMEM250)	OTLJ4G5G	TM250_HUMAN	Increases Expression	[13]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Increases Expression	[22]
Etoposide-induced protein 2.4 homolog (EI24)	OTD4NOYS	EI24_HUMAN	Increases Expression	[22]
Tax1-binding protein 3 (TAX1BP3)	OTQ6IB4T	TX1B3_HUMAN	Increases Expression	[22]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[23]
SLIT-ROBO Rho GTPase-activating protein 3 (SRGAP3)	OT9ZS72C	SRGP3_HUMAN	Decreases Expression	[13]
Histone-lysine N-methyltransferase SUV39H1 (SUV39H1)	OTDTF5BU	SUV91_HUMAN	Increases Expression	[13]
Cytoplasmic protein NCK2 (NCK2)	OTUYPF55	NCK2_HUMAN	Decreases Expression	[22]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Decreases Expression	[22]
A-kinase anchor protein 8 (AKAP8)	OTK3EQAI	AKAP8_HUMAN	Increases Expression	[13]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G)	OT8V1J4M	GA45G_HUMAN	Increases Expression	[11]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7)	OTVT4YA1	ATG7_HUMAN	Increases Expression	[24]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Increases Expression	[24]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Affects Binding	[25]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Phosphorylation	[24]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Expression	[26]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Phosphorylation	[26]
DNA excision repair protein ERCC-1 (ERCC1)	OTNPYQHI	ERCC1_HUMAN	Decreases Expression	[11]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Decreases Expression	[12]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Increases Expression	[22]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[27]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[12]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Decreases Expression	[12]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[12]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Decreases Expression	[12]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1)	OTPWI88U	CEAM1_HUMAN	Increases Expression	[22]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[28]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Decreases Expression	[29]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[24]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR)	OTPDCK1F	ADRO_HUMAN	Increases Expression	[22]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Decreases Expression	[11]
Retinoblastoma-like protein 1 (RBL1)	OTDEBFYC	RBL1_HUMAN	Decreases Expression	[26]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Decreases Expression	[30]
Coilin (COIL)	OTP4I4DL	COIL_HUMAN	Increases Expression	[13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[31]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9)	OTV9L89D	TNFL9_HUMAN	Increases Expression	[22]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases Phosphorylation	[32]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Increases Phosphorylation	[26]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)	OTI2OREX	MP2K3_HUMAN	Increases Expression	[22]
Double-strand break repair protein MRE11 (MRE11)	OTGU8TZM	MRE11_HUMAN	Decreases Expression	[11]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[33]
Transcription factor Sp3 (SP3)	OTYDQZ1T	SP3_HUMAN	Increases Activity	[34]
CCAAT/enhancer-binding protein zeta (CEBPZ)	OT11BATG	CEBPZ_HUMAN	Decreases Expression	[22]
Unconventional myosin-Ie (MYO1E)	OTM9YSIZ	MYO1E_HUMAN	Decreases Expression	[13]
Vesicle transport protein SEC20 (BNIP1)	OT7USYCY	SEC20_HUMAN	Increases Expression	[13]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Increases Expression	[32]
Serine-protein kinase ATM (ATM)	OTQVOHLT	ATM_HUMAN	Decreases Expression	[11]
Cyclin-dependent kinase 5 activator 1 (CDK5R1)	OTJELWK0	CD5R1_HUMAN	Increases Expression	[13]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Decreases Expression	[30]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[22]
EPM2A-interacting protein 1 (EPM2AIP1)	OT21ALNF	EPMIP_HUMAN	Increases Expression	[22]
tRNA-uridine aminocarboxypropyltransferase 1 (DTWD1)	OT95QT6P	DTWD1_HUMAN	Increases Expression	[13]
TBC1 domain family member 16 (TBC1D16)	OTPR3C6A	TBC16_HUMAN	Decreases Expression	[13]
Protein Jumonji (JARID2)	OT14UM8H	JARD2_HUMAN	Decreases Expression	[13]
DNA repair protein RAD50 (RAD50)	OTYMU9G1	RAD50_HUMAN	Decreases Expression	[11]
Small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB)	OTYZL88Z	SGTB_HUMAN	Decreases Expression	[13]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)	OTQR6ENW	M3K5_HUMAN	Decreases Expression	[22]
Tumor protein 63 (TP63)	OT0WOOKQ	P63_HUMAN	Decreases Expression	[35]
Serine/threonine-protein kinase PLK3 (PLK3)	OT19CT2Z	PLK3_HUMAN	Increases Expression	[22]
Sphingomyelin phosphodiesterase 3 (SMPD3)	OTHQBETH	NSMA2_HUMAN	Increases Expression	[36]
PH and SEC7 domain-containing protein 3 (PSD3)	OTTN9B9O	PSD3_HUMAN	Decreases Expression	[13]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Increases Phosphorylation	[24]
Kelch-like protein 42 (KLHL42)	OTK6WARI	KLH42_HUMAN	Increases Expression	[13]
Calcium-binding protein 39 (CAB39)	OT2CL9ST	CAB39_HUMAN	Decreases Expression	[22]
RWD domain-containing protein 3 (RWDD3)	OTE76DY5	RWDD3_HUMAN	Increases Expression	[13]
Integrin-binding sialoprotein (IBSP)	OT29944Y	SIAL_HUMAN	Decreases Response To Substance	[14]
E3 ubiquitin-protein ligase RNF31 (RNF31)	OT4BZONL	RNF31_HUMAN	Decreases Response To Substance	[14]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Decreases Response To Substance	[14]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E)	OT8GPFT5	2A5E_HUMAN	Decreases Response To Substance	[37]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A)	OT9297OG	2ABA_HUMAN	Decreases Response To Substance	[37]
Cytochrome P450 26B1 (CYP26B1)	OT92XA92	CP26B_HUMAN	Decreases Response To Substance	[14]
Retinoblastoma-like protein 2 (RBL2)	OTBQSOE6	RBL2_HUMAN	Decreases Response To Substance	[26]
Protein sel-1 homolog 1 (SEL1L)	OTC0FB7T	SE1L1_HUMAN	Decreases Response To Substance	[14]
Protein prenyltransferase alpha subunit repeat-containing protein 1 (PTAR1)	OTCT7YPX	PTAR1_HUMAN	Decreases Response To Substance	[14]
Lipid scramblase CLPTM1L (CLPTM1L)	OTDJWQXI	CLP1L_HUMAN	Increases Response To Substance	[38]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C)	OTF7CGO2	2A5G_HUMAN	Increases Response To Substance	[37]
DNA repair endonuclease XPF (ERCC4)	OTFIOPG1	XPF_HUMAN	Decreases Response To Substance	[28]
Receptor-type tyrosine-protein phosphatase O (PTPRO)	OTFLKWOY	PTPRO_HUMAN	Decreases Response To Substance	[14]
Cone-rod homeobox protein (CRX)	OTH435SV	CRX_HUMAN	Decreases Response To Substance	[14]
Disintegrin and metalloproteinase domain-containing protein 19 (ADAM19)	OTH88TXU	ADA19_HUMAN	Decreases Response To Substance	[14]
Leucine-rich repeat and calponin homology domain-containing protein 4 (LRCH4)	OTJFA4AV	LRCH4_HUMAN	Decreases Response To Substance	[14]
Homeobox protein Hox-A1 (HOXA1)	OTMSOJ7D	HXA1_HUMAN	Decreases Response To Substance	[14]
Myotubularin-related protein 2 (MTMR2)	OTNCYGBP	MTMR2_HUMAN	Decreases Response To Substance	[14]
Olfactory receptor 7C2 (OR7C2)	OTO7MWWV	OR7C2_HUMAN	Decreases Response To Substance	[14]
A-kinase anchor protein 13 (AKAP13)	OTOZAR14	AKP13_HUMAN	Decreases Response To Substance	[14]
TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (TAB2)	OTPZK76F	TAB2_HUMAN	Decreases Response To Substance	[14]
ARF GTPase-activating protein GIT2 (GIT2)	OTQ2EQJ1	GIT2_HUMAN	Decreases Response To Substance	[14]
Phospholipid hydroperoxide glutathione peroxidase GPX4 (GPX4)	OTRAFFX2	GPX4_HUMAN	Decreases Response To Substance	[14]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Response To Substance	[14]
MTRF1L release factor glutamine methyltransferase (HEMK1)	OTSHNL5K	HEMK1_HUMAN	Decreases Response To Substance	[14]
Protein phosphatase 1 regulatory subunit 1B (PPP1R1B)	OTSIJMQ9	PPR1B_HUMAN	Decreases Response To Substance	[39]
Serine/threonine/tyrosine-interacting-like protein 1 (STYXL1)	OTSPVITK	STYL1_HUMAN	Decreases Response To Substance	[14]
Apoptosis-inducing factor 3 (AIFM3)	OTSWKCAO	AIFM3_HUMAN	Decreases Response To Substance	[14]
Serine/threonine-protein kinase Chk1 (CHEK1)	OTTTI622	CHK1_HUMAN	Decreases Response To Substance	[14]
DNA repair protein RAD51 homolog 3 (RAD51C)	OTUD6SY5	RA51C_HUMAN	Increases Response To Substance	[40]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Response To Substance	[41]
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7)	OTUXEASC	M3K7_HUMAN	Decreases Response To Substance	[14]
Olfactory receptor 1A2 (OR1A2)	OTVRC7A5	OR1A2_HUMAN	Decreases Response To Substance	[14]
Artemin (ARTN)	OTWIWGL6	ARTN_HUMAN	Decreases Response To Substance	[14]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A)	OTYA3GB4	2AAA_HUMAN	Decreases Response To Substance	[14]
Protein phosphatase 1 regulatory inhibitor subunit 16B (PPP1R16B)	OTZJFX5C	PP16B_HUMAN	Decreases Response To Substance	[14]
Ataxin-3-like protein (ATXN3L)	OTZV3BG4	ATX3L_HUMAN	Decreases Response To Substance	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 121 DOT(s)

Indication(s) of Ruxolitinib

Disease Entry	ICD 11	Status	REF
Essential thrombocythemia	3B63.1Z	Approved	[3]
High-risk myelofibrosis	2A20.2	Approved	[4]
Myelofibrosis	2A22	Approved	[5]
Myeloproliferative neoplasm	2A20	Approved	[6]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[7]
Pancreatic cancer	2C10	Phase 3	[4]
Atopic dermatitis	EA80	Phase 1/2	[8]
Vitiligo	ED63.0	Phase 1/2	[8]

Ruxolitinib Interacts with 5 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Modulator	[42]
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Modulator	[42]
Urokinase plasminogen activator surface receptor (PLAUR)	TTPRL03	UPAR_HUMAN	Inhibitor	[43]
HUMAN janus kinase 1 (JAK-1)	TTWKB01	JAK1_HUMAN	Inhibitor	[44]
HUMAN janus kinase 2 (JAK-2)	TT0F5HE	JAK2_HUMAN	Inhibitor	[44]
------------------------------------------------------------------------------------

Ruxolitinib Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Increases ADR	[45]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Ruxolitinib FDA Label
7	Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
10	Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes. Environ Toxicol. 2019 Apr;34(4):401-414.
11	Myristicin from nutmeg induces apoptosis via the mitochondrial pathway and down regulates genes of the DNA damage response pathways in human leukaemia K562 cells. Chem Biol Interact. 2014 Jul 25;218:1-9. doi: 10.1016/j.cbi.2014.04.014. Epub 2014 Apr 29.
12	Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
13	Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
14	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
15	Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep. 2005 Nov;14(5):1311-6.
16	PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response. Cell Biol Toxicol. 2023 Feb;39(1):345-364. doi: 10.1007/s10565-022-09739-9. Epub 2022 Jul 1.
17	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
18	The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
19	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20	Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
21	Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
22	Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
23	SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes. Toxicol Appl Pharmacol. 2014 Jun 15;277(3):288-97. doi: 10.1016/j.taap.2014.04.001. Epub 2014 Apr 12.
24	Camptothecin enhances c-Myc-mediated endoplasmic reticulum stress and leads to autophagy by activating Ca(2+)-mediated AMPK. Food Chem Toxicol. 2018 Nov;121:648-656. doi: 10.1016/j.fct.2018.09.057. Epub 2018 Sep 25.
25	Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007 May-Jun;18(3):702-16. doi: 10.1021/bc0602735. Epub 2007 Mar 23.
26	pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
27	Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun. 2001 Dec 21;289(5):998-1009. doi: 10.1006/bbrc.2001.6073.
28	Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011 May;39(9):3607-20. doi: 10.1093/nar/gkq1304. Epub 2011 Jan 11.
29	Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol Pharmacol. 2008 Aug;74(2):517-26. doi: 10.1124/mol.107.043620. Epub 2008 May 20.
30	Effects of folic acid on the antiproliferative efficiency of doxorubicin, camptothecin and methyl methanesulfonate in MCF-7 cells by mRNA endpoints. Saudi J Biol Sci. 2018 Dec;25(8):1568-1576. doi: 10.1016/j.sjbs.2016.02.005. Epub 2016 Feb 10.
31	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
32	Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathway. Food Chem Toxicol. 2019 May;127:143-155. doi: 10.1016/j.fct.2019.03.026. Epub 2019 Mar 15.
33	Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact. 2009 Oct 7;181(2):185-92. doi: 10.1016/j.cbi.2009.05.013. Epub 2009 May 27.
34	Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 2001 Mar;49(3):345-54.
35	p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells. Biochem Pharmacol. 2013 Apr 1;85(7):999-1006. doi: 10.1016/j.bcp.2013.01.019. Epub 2013 Jan 29.
36	Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
37	PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
38	Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One. 2012;7(6):e36116. doi: 10.1371/journal.pone.0036116. Epub 2012 Jun 4.
39	Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res. 2005 Aug 1;65(15):6583-92. doi: 10.1158/0008-5472.CAN-05-1433.
40	Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
41	The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell. 2011 Sep;22(17):3032-40. doi: 10.1091/mbc.E11-04-0280. Epub 2011 Jul 7.
42	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
43	Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
44	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
45	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.